SciClone is excited to announce that on March 8th, March 9th, and March 16th they will be presenting at Investor Conferences. The three conferences are Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. Updates and overviews will be presented at each of these conferences.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About SciClone
SciClone Pharmaceuticals is a profit-focused, global specialty pharmaceutical company with a substantial international business, based primarily in the People's Republic of China, and with a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN® (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it will seek regulatory approval.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
